What is the recommended empagliflozin (Jardiance) dose for patients with heart failure with preserved ejection fraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Empagliflozin (Jardiance) Dose for HFpEF

The recommended dose of empagliflozin for heart failure with preserved ejection fraction (HFpEF) is 10 mg once daily.

Evidence-Based Dosing

The 10 mg daily dose is firmly established across multiple high-quality guidelines and the pivotal EMPEROR-Preserved trial 1, 2, 3. This is a fixed dose—not a starting dose requiring titration. The FDA-approved labeling confirms empagliflozin 10 mg once daily for adults with heart failure regardless of ejection fraction 4.

Key Trial Data

In EMPEROR-Preserved, 5,988 patients with LVEF >40% received empagliflozin 10 mg daily versus placebo, demonstrating:

  • 21% reduction in cardiovascular death or heart failure hospitalization (HR 0.79,95% CI 0.69-0.90) 1, 5
  • 29% reduction in first heart failure hospitalization (HR 0.71,95% CI 0.60-0.83) 2
  • Benefits consistent regardless of diabetes status 1, 6
  • Median follow-up of 26.2 months 1, 5

Why Not 25 mg?

The 25 mg dose studied in type 2 diabetes trials was never evaluated in the HFpEF population. The EMPEROR-Preserved trial specifically used 10 mg daily, and this is the only dose with proven efficacy for heart failure outcomes 1, 2, 5. The most recent 2025 Canadian guidelines explicitly list empagliflozin 10 mg daily as both the starting and target dose for HFnrEF (which includes HFpEF) 7.

Practical Implementation

Initiation:

  • Start 10 mg once daily immediately upon diagnosis
  • No titration required
  • Can be initiated in both inpatient and outpatient settings 3

Renal Considerations:

  • Safe down to eGFR ≥20 mL/min/1.73 m² based on trial enrollment 1, 8, 4
  • Contraindicated in patients on dialysis 4
  • No dose adjustment needed for renal impairment above this threshold 4

Common Pitfalls to Avoid:

  • Do not use the 25 mg dose for HFpEF—this lacks evidence and exceeds studied exposure levels 9
  • Do not delay initiation waiting for "optimization" of other therapies—empagliflozin can be started early 8
  • Do not discontinue in patients who develop mild eGFR decline—this is expected and reversible 4

Safety Profile

The 10 mg dose demonstrated favorable tolerability in HFpEF patients 1, 5:

  • Increased genital and urinary tract infections (manageable)
  • Mild hypotension risk (monitor in volume-depleted patients)
  • No excess hypoglycemia in non-diabetic patients 6
  • Temporary eGFR decline that stabilizes and reverses after discontinuation 4

Volume status assessment before initiation is critical—correct volume depletion first, especially in patients ≥75 years who have higher risk 4.

Guideline Consensus

The 2023 ACC Expert Consensus 3, 2023 ADA Standards 1, 2025 Canadian guidelines 7, and 2022 Canadian CCS/CHFS guidelines 2 all uniformly recommend empagliflozin 10 mg daily for HFpEF. This represents a Strong Recommendation with High-Quality Evidence across all major societies 7, 2.

Related Questions

In a heart failure patient taking carvedilol, spironolactone, valsartan, furosemide, and empagliflozin (Jardiance) 10 mg daily who has hypotension, should the empagliflozin be held or its dose adjusted?
Can I start empagliflozin (Jardiance) 10 mg daily for my heart failure with preserved ejection fraction and iron‑deficiency anemia, given my eGFR is ≥20 mL/min/1.73 m² and I am already on diuretics, an ACE‑inhibitor/ARB/ARNI, and a mineralocorticoid‑receptor antagonist?
What are the benefits of initiating empagliflozin (10 mg) once daily in a patient with chronic heart failure (reduced or preserved ejection fraction) who does not have type 1 diabetes, active ketoacidosis, or an eGFR < 30 mL/min/1.73 m²?
Are empagliflozin (Jardiance) and eplerenone appropriate for a patient with preserved left ventricular ejection fraction, mild left‑ventricular chamber enlargement and grade 1 diastolic dysfunction, despite lacking systolic dysfunction?
What is the recommended empagliflozin (Jardiance) dosing for guideline‑directed medical therapy in patients with heart failure with reduced ejection fraction, including dose adjustments based on renal function?
What does an enlarged prostate with T2‑hypointense signal on MRI indicate, and what diagnostic and management steps should be taken?
At what blood glucose level should I call emergency services (911)?
In a patient aged 70 or older without known atherosclerotic cardiovascular disease, should routine low‑dose aspirin be used for primary prevention?
If a rheumatoid factor (RF) test is negative once, will it always remain negative?
What are the differences between cefazolin and ceftriaxone?
Is the serum protein-to-creatinine ratio the same as the urine protein-to-creatinine ratio?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.